ORKA Oruka Therapeutics, Inc.
Healthcare$60.61+3.27%ClosedMarket Cap: $2.27B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
6.87
P/S
0.00
EV/EBITDA
-17.69
DCF Value
$0.90
FCF Yield
-4.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-26.0%
ROA
-23.0%
ROIC
-27.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-36.4M | $-31.8M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-34.4M | $-29.6M | $— | — |
| FY null | $0.00 | -Infinity% | $-122.1M | $-105.4M | $— | — |
| Q3 null | $0.00 | NaN% | $-34.1M | $-30.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-28.4M | $-24.6M | $— | — |
| Q1 null | $0.00 | NaN% | $-25.1M | $-21.0M | $— | — |
| Q4 null | $0.00 | NaN% | $-38.3M | $-33.4M | $— | — |
| FY null | $0.00 | -Infinity% | $-88.1M | $-83.7M | $— | $1.61 |
| Q3 null | $0.00 | NaN% | $-29.4M | $-28.6M | $— | $1.61 |
| Q2 null | $0.00 | NaN% | $-21.5M | $-22.2M | $— | — |
| Q1 null | $0.00 | -Infinity% | $-2.5M | $-2.0M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-1.6M | $-1.1M | $-0.90 | — |